Latest Conference Articles

Aggarwal Lends Insight on the Use of TKIs and Liquid Biopsies in ALK+ NSCLC

Charu Aggarwal, MD, MPH, discusses the current state of treatment for patients with ALK-positive non–small cell lung cancer, the utility of liquid biopsy, and remaining questions that need to be addressed in the space.

Bunn Breaks Down the Latest With Antibody-Drug Conjugates in Lung Cancer

Although antibody-drug conjugates have yet to receive regulatory approval in the lung cancer space, several emerging agents are showing early promise in clinical trials.

TRK Inhibitors Are a Safe, Effective Option in TRK Fusion-Positive Cancers

Clinical data shows that the TRK inhibitors entrectinib and larotrectinib induce high response rates with favorable toxicity profiles and central nervous system penetration, and are a viable treatment option for patients with advanced TRK fusion-positive cancers.

Moving Toward Newfound Diagnostic, Treatment Paradigms in Lung Cancer

Ignacio I. Wistuba, MD, discusses the clinical importance of histological subtyping of lung cancer and additional parameters such as driver alterations, alternative methods for molecular testing, and immunotherapy-related biomarkers have strengthened the diagnostic and treatment paradigms in lung cancer.

New Tools Support Translational Strides in NSCLC

In non–small cell lung cancer, single cell analytics, genome editing, and next-generation animal models represent just some of the modern modalities advancing translational research.

Adjuvant Osimertinib Possesses Potential to Revolutionize NSCLC Treatment, But Longer Follow-Up Needed

The disease-free survival benefit observed with the third-generation EGFR TKI osimertinib as an adjuvant treatment in patients with EGFR-mutant non–small cell lung cancer in the phase 3 ADAURA trial is striking.

Dr. Aggarwal on Emerging Treatment Approaches in ALK+ NSCLC

Charu Aggarwal, MD, MPH, discusses emerging treatment approaches in ALK-positive non–small cell lung cancer.

Dr. Gandara on the Utility of TMB in NSCLC

David R. Gandara, MD, discusses the utility of tumor mutational burden in non–small cell lung cancer.

Leveraging CDK4/6 Inhibitors in Earlier Settings to Boost Outcomes in HR+ Breast Cancer

Angela DeMichele, MD, MSCE, shares how to utilize available data with CDK4/6 inhibitors in the neoadjuvant and adjuvant settings to optimize outcomes for patients with hormone receptor–positive breast cancer.

Dr. Mamounas on Recurrence Rates in Breast Cancer

Terry P. Mamounas, MD, MPH, FACS, discusses common recurrence rates in breast cancer.

Key Data Inform Treatment Decisions in Early HER2+ Breast Cancer

The growing number of treatments within the HER2-positive breast cancer armamentarium signals a need to redefine and tailor neoadjuvant and adjuvant strategies to individual patients.

Dr. Tolaney on Deescalating Therapy in Stage I HER2+ Breast Cancer

Sara M. Tolaney, MD, MPH, discusses appropriately deescalating treatment to reduce toxicities in stage I HER2-positive breast cancer.

Metastatic HER2+ Breast Cancer Treatment Must Move to Personalized Approach

The optimal sequence of therapies for patients with metastatic HER2-positive breast cancer must be an individualized one, and should be dependent on the presence and/or level of central nervous system disease.

Carving Out New Combination Therapies in Stem Cell Disorders

Despite the influx of novel agents that have received regulatory approval in recent years in stem cell disorders, there is still room for improvement.

Rini Reviews Key ASCO 2020 Highlights in Genitourinary Cancers

As part of the 2020 ASCO Direct Highlights™ webcast, Brian Rini, MD, discusses key developments in genitourinary cancers that were presented during the 2020 ASCO Virtual Scientific Program.

Experts Explore Treatment Approaches With Novel Agents in ALL

A panel of experts in acute lymphoblastic leukemia broach the topic of innovative approaches incorporating novel agents in clinical practice.

Panel of Experts Cover Clinical Scenarios in AML

A panel of experts in acute myeloid leukemia (AML) consider potential treatment options for patients with AML

CML Experts Consider Challenging Cases Faced in Clinical Practice

A panel of experts in chronic myeloid leukemia share insight on how to optimally approach treatment based on patient characteristics.

Dr. Raje on Key Challenges Faced in Multiple Myeloma

Noopur Raje, MD, discusses the current challenges faced in the multiple myeloma treatment paradigm.

Dr. Leslie on Remaining Questions to Address in MCL

Lori Leslie, MD, discusses key questions to address with future research efforts in mantle cell lymphoma.

Postow Presents Progress Made in Melanoma

Immunotherapy and BRAF plus MEK inhibition are the key players in the treatment of patients with melanoma, Michael Postow, MD, said in a presentation during the 2020 ASCO Direct Highlights webcast.

Singal Speaks to ASCO Highlights in Rapidly Evolving HCC Paradigm

The treatment landscape of advanced hepatocellular carcinoma has been subject to rapid development in the last few years, says Amit G. Singal, MD, MS.

ASCO 2020 Heralds a Handful of Influential Data Across Breast Cancer Settings

The 2020 ASCO Virtual Scientific Program delivered a number of important updates to the field of breast cancer, explained Joyce A. O'Shaughnessy, MD.

Dr. Kim on Efficacy and Next Steps With Regorafenib/Nivolumab Combo in CRC

Richard D. Kim, MD, discusses the efficacy of and next steps for a phase 1/1b study with regorafenib and nivolumab in patients with mismatch repair proficient advanced refractory colorectal cancer.

Later-Line Infigratinib Outperforms Standard Chemotherapy in Cholangiocarcinoma

Infigratinib conferred a clinically meaningful progression-free survival and overall response rate benefit when administered as a third- and later-line treatment for patients with FGFR2 fusion–positive cholangiocarcinoma.

Wainberg Weighs in on Favorable Frontline Activity With NALIRIFOX Regimen in Pancreatic Cancer

Zev. A. Wainberg, MD, discusses findings from a phase 1/2 study of NALIRIFOX in patients with pancreatic ductal adenocarcinoma.

EDP1503 With or Without Pembrolizumab Has Clinical Activity Across Solid Tumors

EDP1503, an investigational monoclonal microbial product, was safe and well-tolerated when administered in combination with pembrolizumab (Keytruda), and mechanistically drove some of the patient responses seen in a phase 1/2 study.

Dr. Yoon on Updated Results of the KEYNOTE-061 Study in Advanced Gastric/GEJ Cancer

Harry H. Yoon, MD, discusses the updated results of the phase 3 KEYNOTE-061 trial in advanced gastric/gastroesophageal junction (GEJ) cancer.

Irinotecan Monotherapy Shows Similar Activity, Improved Safety as Chemo Combo in Advanced Gallbladder Cancer

Irinotecan monotherapy demonstrated similar clinical activity and improved safety compared with capecitabine plus irinotecan in patients with advanced gallbladder cancer, representing a potential second-line treatment for frail patients.

Dr. Ramaswamy on Capecitabine and Irinotecan Monotherapy in Gallbladder Cancer

Anant Ramaswamy, MD, discusses a phase 2 multicenter clinical trial evaluating the efficacy of capecitabine plus irinotecan versus irinotecan monotherapy in advanced gallbladder cancer.